Ocular Therapeutix vs. Prime Medicine: Which Healthcare Stock Is a Better Buy in 2026?
Two biotech innovators, two very different risk profiles: one with commercial products and another betting on next-gen gene editing breakthroughs.
Ocular Therapeutix vs. Prime Medicine: Which Healthcare Stock Is a Better Buy in 2026?
Overview
Ocular Therapeutix (NASDAQ:OCUL) and Prime Medicine (NASDAQ:PRME) represent two distinct paths within the high-risk, high-reward world of medical innovation. Choosing between them requires balancing established commercial revenue against moonshot therapeutic potential.
Ocular Therapeutix specializes in bioresorbable hydrogel technology to deliver medicine directly to the eye. Meanwhile, Prime Medicine focuses on its proprietary Prime Editing technology, which functions like a DNA word processor. Both companies target massive unmet needs in human health, but operate at very different stages of corporate maturity.
Details
As one of the many biotech stocks investors are watching, Ocular Therapeutix focuses on treating retinal diseases. Its lead commercial product, Dextenza, is an insert for treating inflammation and pain after ophthalmic surgery. The company relies on three specialty distributors for roughly 75% of its 2025 revenue, which adds a layer of risk to the business.
Source
Originally published at www.fool.com.
